Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AST-120 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AST-120 (6g) | EXPERIMENTAL | 2 grams TID |
| Placebo A | PLACEBO_COMPARATOR | 2 grams TID |
| AST-120 (12g) | EXPERIMENTAL | 4 grams TID |
| Placebo B | PLACEBO_COMPARATOR | 4 grams TID |
| Name | Type | Description |
|---|---|---|
| AST-120 | DRUG | AST-120 |
Inclusion Criteria: 1. Confirmed cirrhosis of any cause 2. Abnormal RBANS global summary score 3. Grade 0 or 1 hepatic encephalopathy by West-Haven Scale 4. MELD score \< or = 25 5. Females must be postmenopausal, surgically incapable of bearing children or practicing a reliable method of birth con...
AST-120 is an investigational small molecule being studied for the treatment of mild hepatic encephalopathy, a condition related to gastrointestinal and liver function. It is currently in Phase 2 clinical development and has not been approved by the FDA.
AST-120 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The drug is currently in Phase 2 clinical trials for mild hepatic encephalopathy.
AST-120 is in Phase 2 clinical development. It is an investigational drug and has not yet received FDA approval. A Phase 2 clinical trial for mild hepatic encephalopathy has been completed.
AST-120 has been studied in a Phase 2 clinical trial with the identifier NCT00867698. This trial, titled "AST-120 Used to Treat Mild Hepatic Encephalopathy," was completed and enrolled 148 participants in the United States.
Yes, AST-120 has been evaluated in a randomized, double-blind, placebo-controlled clinical trial. This Phase 2 study enrolled 148 participants with mild hepatic encephalopathy and was completed in the United States.